Pediatric Nephrology

, Volume 25, Issue 9, pp 1597–1606 | Cite as

Vitamin D insufficiency: implications for the immune system

  • Femke Baeke
  • Conny Gysemans
  • Hannelie Korf
  • Chantal Mathieu


Chronic kidney disease (CKD) is characterized by a loss of kidney function and dysregulation of vitamin D metabolism. Well known are the defects in final activation of vitamin D to 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], resulting in renal osteodystrophy. However, in recent years, 1,25(OH)2D3 has been identified as having effects far beyond calcium and bone metabolism. In this review, specific attention is given to the effects of 1,25(OH)2D3 on the immune system and the implications of vitamin D deficiency, a feature of many patients with CKD, on immune function.


Vitamin D Immune modulation Chronic kidney disease 


Vitamin D insufficiency is a term used to describe the biochemical evidence of deficiency without obvious clinical signs or symptoms, such as rickets or osteomalacia. Although there is continuing discussion about the precise levels of 25-hydroxyvitamin D3 [25(OH)D3], which define the different categories of vitamin D status, there is general agreement that vitamin D insufficiency or hypovitaminosis D is prevalent in many populations across the globe. Vitamin D insufficiency is most commonly diagnosed by a serum concentration of 25(OH)D3 between 15 and 30 ng/ml; levels <15 ng/ml are defined as vitamin D deficiency, with concentrations <5 ng/ml being severely deficient and associated with presentation of osteomalacia and rickets [1]. Currently, serum concentrations of 30–50 ng/ml 25(OH)D3 are accepted to meet the requirements for vitamin D sufficiency; however, recent evidence suggests that the optimal serum 25(OH)D3 levels may be much higher [2, 3]. Vitamin D insufficiency has been reported to cause muscle weakness and may contribute to falls in the elderly, which—when associated with osteoporosis—increases the likelihood of fractures [4]. However, more recent evidence indicates that vitamin D insufficiency and certainly deficiency might also be associated with diseases such as colorectal cancer, prostate cancer, multiple sclerosis, type 1 diabetes, cardiovascular diseases, and tuberculosis [5]. In this review, we focus on the effects of vitamin D insufficiency/deficiency on the immune system.

Sources and metabolism of vitamin D

Vitamin D is an essential nutrient for mineral homeostasis and bone metabolism, being available in two distinct forms, ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3). The first is a fungus/yeast-derived product and can be produced through ultraviolet (UV) exposure of foods, whereas the latter is mainly provided by UV-mediated synthesis in the epidermal layer of the skin but also by nutritional intake (e.g. fatty fish, cod liver oil, and fortified dairy products). Upon sunlight exposure, photolytic cleavage of 7-dihydrocholesterol in the skin results in the formation of previtamin D3, which is subsequently converted by a spontaneous thermal isomerization into vitamin D3 [6]. For systemic transport, vitamin D3 and its metabolites, either produced by the skin or absorbed in the gastrointestinal tract, are bound by a carrier molecule, vitamin-D-binding protein (DBP). To become bioactive, inactive vitamin D3 is subjected to two subsequent hydroxylation steps [7]. The first step, hydroxylation of vitamin D3 at the carbon-25 position resulting in formation of 25(OH)D3, occurs primarily in the liver and is catalyzed by 25-hydroxylase. Among the family of P450-containing enzymes (CYPs), there are several candidates to perform the first hydroxylation, including CYP27A1, CYP2C11, CYP2R1, and CYP3A4; but CYP2R1 has been demonstrated to be the high affinity 25-hydroxylase. The second hydroxylation step occurs predominantly in the proximal tubule cells of the kidney and is carried out by 1-α-hydroxylase (CYP27B1), resulting in production of the biologically active metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3).

As 1,25(OH)2D3 is critically involved in the maintenance of adequate serum calcium and phosphate levels, its production is tightly controlled by these minerals. As 25-hydroxylase is poorly regulated, leading to a conversion of almost all vitamin D present into 25(OH)D3, 25(OH)D3 is the major circulating form of vitamin D and its concentration is commonly used as an indicator of vitamin D status. On the other hand, 1-α-hydroxylase activity is precisely regulated by a variety of factors, including serum calcium, phosphate, parathyroid hormone (PTH), and 1,25(OH)2D3 itself [7]. Low serum calcium levels trigger the release of PTH from the parathyroid glands, which in turn increases renal 1-α-hydroxylase activity and subsequent 1,25(OH)2D3 production. In order to correct serum calcium levels, 1,25(OH)2D3 decreases renal calcium excretion and stimulates intestinal calcium absorption and osteoclast maturation to release calcium from the bones. When normocalcemia is obtained, PTH release is shut down and 1-α-hydroxylase activity is not longer stimulated. Other important negative regulators of 1-α-hydroxylase activity include fibroblast growth factor (FGF)-23 and Klotho proteins [7]. 1,25(OH)2D3 itself induces expression of 24-hydroxylase (CYP24A1), the enzyme that accomplishes the first step of 1,25(OH)2D3 catabolism, eventually triggering its own degradation [7]. This negative feedback mechanism probably serves as an internal rescue to avoid excessive vitamin D signaling.

Mechanism of action of 1,25(OH)2D3

Most biological effects of 1,25(OH)2D3 are mediated by binding of the ligand to its receptor, the vitamin D receptor (VDR), a member of the nuclear receptor superfamily [7]. Upon ligand binding, this nuclear receptor heterodimerizes with the retinoid X receptor (RXR). Next, this complex binds to vitamin-D-responsive elements (VDREs) located in the promoter region of target genes in order to regulate their transcription. Interaction between the ligand-VDR-RXR complex and a VDRE results in the release of corepressors and recruitment of nuclear receptor coactivator proteins, thereby inducing chromatin remodeling and attracting key components of the transcription initiation complex. Alternatively, when ligand-VDR-RXR is recruited to an inhibitory VDRE, corepressors are recruited and transcription of the gene is inhibited. Besides its genomic actions, rapid nongenomic signaling events occurring within seconds or minutes upon 1,25(OH)2D3 exposure have been reported in different cell types [7, 8]. Importantly, VDR expression is not restricted to cells involved in mineral homeostasis and bone metabolism. The presence of this nuclear receptor has also been demonstrated in many other cell types, including normal cells (e.g. keratinocytes, pancreatic β-cells) and malignant cells (e.g. leukemia cells; breast, prostate, and colon cancer cells), allowing 1,25(OH)2D3 to expand its effects far beyond calcium and bone homeostasis (reviewed in [9]). Indeed, 1,25(OH)2D3 affects growth, differentiation status, and function of many other cell types. The discovery that various target cells of 1,25(OH)2D3 produce the enzymes necessary for vitamin D activation caused a major breakthrough in understanding the nonclassic actions of 1,25(OH)2D3. Extrarenal expression of 1-α-hydroxylase and in some cells also 25-hydroxylase allows the local auto- or paracrine production and regulation of 1,25(OH)2D3 without affecting serum concentrations of the hormone [10]. These findings emphasize the importance of adequate vitamin D levels, not only to maintain bone health, but for global health.

Vitamin D and the immune system

Expression of the VDR and vitamin D metabolizing enzymes is not restricted to cells involved in calcium and bone metabolism. Within the immune system, VDR is expressed by almost all immune cells, including activated CD4+ and CD8+ T cells, B cells, neutrophils, and antigen-presenting cells (APCs), such as macrophages and dendritic cells (DCs) [11, 12, 13]. In addition, the key enzymes needed for vitamin D activation and degradation are expressed by certain immune cells. 1-α-hydroxylase has been detected in macrophages, DCs, and even B- and T cells [14, 15, 16, 17, 18]. Although being identical to the renal enzyme, expression of 1-α-hydroxylase in macrophages is upregulated by immune signals such as interferon (IFN)-γ and lipopolysaccharide (LPS) or viral infections (reviewed in [19]). In DCs, upregulation of 1-α-hydroxylase is associated with the maturation process of these cells, suggesting that local production of 1,25(OH)2D3 might serve as a negative feedback loop to prevent excessive inflammation [16]. Simultaneously, maturation of DCs is accompanied by a decrease in VDR-expression, making them less responsive to 1,25(OH)2D3 as they mature. In contrast with 1-α-hydroxylase regulation in kidney, neither in macrophages nor in DCs is 1-α-hydroxylase activity subjected to negative feedback signals from 1,25(OH)2D3 itself, offering an explanation for the massive local production of 1,25(OH)2D3 by disease-associated macrophages seen in patients with granulomatous diseases (sarcoidosis and tuberculosis) [15, 16]. Next to 1-α-hydroxylase, expression of 25-hydroxylase and 24-hydroxylase by immune cells has been reported [16, 17, 18]. However, the ability of 1,25(OH)2D3 to induce 24-hydroxylase in monocytes and macrophages depends on the differentiation/maturation stage of the cells. Undifferentiated monocytes are highly susceptible to 1,25(OH)2D3-mediated 24-hydroxylase induction, whereas differentiated/activated macrophages are resistant [20].

Together, the presence of VDR and the regulated expression of vitamin-D-metabolizing enzymes in immune cells allow local conversion of vitamin D into its biologically active form. Indeed, a growing amount of data demonstrate functional responses of immune cells to inactive vitamin D metabolites, including vitamin D3 and 25(OH)D3 [16, 18, 21]. Local vitamin D metabolism from its inactive precursors offers an attractive mechanism for immune cells to reach levels of 1,25(OH)2D3, far exceeding serum concentrations in order to modulate immune responses, without affecting systemic levels of this hormone. Together, these data provide strong evidence for an auto- and/or paracrine role for 1,25(OH)2D3 in normal immune physiology.

Vitamin D: enhancer of innate immune responses

The physiological importance of vitamin D and its active metabolite in the immune system is further emphasized by multiple studies linking vitamin D insufficiency/deficiency to aberrant immune responses. Multiple groups have reported a relation between vitamin D deficiency and susceptibility to infections, especially in the context of infection by Mycobacterium tuberculosis. A higher susceptibility to tuberculosis is seen in patients with relatively low serum vitamin D levels, such as the elderly, uremic patients, and dark-skinned people [22]. Monocytes and macrophages are key players in mounting innate immune responses against various infectious agents, including bacteria, viruses, fungi, and parasites, as they rapidly detect pathogen-associated molecular patterns (PAMPs) of dangerous microbial invaders by means of pattern-recognition receptors, such as toll-like receptors (TLRs). We and others identified various defects in macrophage functions indispensable for antimicrobial activity in vitamin-D-deficient mice, including defects in chemotaxis, phagocytosis, and proinflammatory cytokine production [23, 24]. In accordance with these observations, experimental data demonstrate the ability of 1,25(OH)2D3 to stimulate innate immune responses (Fig. 1). 1,25(OH)2D3 exerts prodifferentiating effects on monocytes and monocyte-derived cell lines, driving them toward a macrophage-like phenotype [25]. In addition, exposing macrophages to 1,25(OH)2D3 enhances their chemotactic and phagocytic capacity, which is indispensable for their tumor-cell cytotoxicity and antimicrobial activity [26]. 1,25(OH)2D3 is known to protect cultured human monocytes and macrophages against tubercle bacilli [27].
Fig. 1

Immunomodulatory effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. Different immune cells express 1-α-hydroxylase (1αOHase), allowing them to convert circulating 25-hydroxyvitamin D3 [25(OH)D3] into bioactive 1,25(OH)2D3. Locally produced 1,25(OH)2D3 can act in an auto- or paracine fashion to modulate both innate and adaptive immune responses. 1,25(OH)2D3 inhibits the expression of costimulatory molecules (CD40, CD80, CD86) and major histocompatability complex II (MHCII) on the surface of antigen-presenting cells [including dendritic cells (DC)] and inhibits production of inflammatory cytokines such as interleukin (IL)-12 and IL-23 while stimulating the release of anti-inflammatory IL-10. By this, 1,25(OH)2D3 indirectly shifts CD4+ T-cell polarization from an inflammatory T-helper (Th)1 and Th17 to a protective Th2 and regulatory T-cell (Treg) phenotype. Also, 1,25(OH)2D3 directly modulates T-cell responses by inhibition of inflammatory Th1 and Th17 cytokines and upregulation of Th2 cytokines. Together through these actions, 1,25(OH)2D3 reduces tissue inflammation by macrophages (mØ), neutrophils (N°), and cytotoxic T cells (Tc). These integrated effects of 1,25(OH)2D3 on the adaptive immune system might contribute to the prevention of autoimmune diseases and other chronic inflammatory conditions. On the other hand, 1,25(OH)2D3 increases the ability of monocytes (mon)/macrophages to combat threatening pathogens by enhancing their chemotactic and phagocytotic capacities but also by stimulating production of reactive oxygen species and antimicrobial proteins, such as cathelicidin and defensin beta 4, thereby allowing the efficient clearance of pathogens such as M. tuberculosis

Recently, a central mechanism underlying the antimicrobial effects of 1,25(OH)2D3 was identified: 1,25(OH)2D3 induces expression of cathelicidin antimicrobial peptide (CAMP) in various cell types, including myeloid cells, keratinocytes, neutrophils, and bronchial epithelial cells, directly leading to enhanced antimicrobial activity [28, 29, 30]. Interestingly, 1,25(OH)2D3-mediated induction of CAMP was found to be an integral component of human TLR-mediated immune responses: TLR2/1-triggering of human monocytes selectively induces expression of VDR and 1-α-hydroxylase, making the cells able to convert 25(OH)D3 into active 1,25(OH)2D3 and allowing the 1,25(OH)2D3-mediated induction of CAMP [21]. Therefore, adequate functioning of this antimicrobial mechanism critically depends on the presence of 25(OH)D3 in the medium: TLR2/1-stimulated production of CAMP was severely impaired when monocytes were cultured with serum from dark-skinned African Americans, as this serum contains low levels of 25(OH)D3 due to lower vitamin D production in dark skin. Addition of 25(OH)D3 to the medium could indeed restore impaired CAMP production. Recently, Krutzik et al. discovered IL-15 as the factor responsible for TLR2/1-mediated induction of VDR and 1-α-hydroxylase in monocytes [31]. Remarkably, induction of CAMP is not the only mechanism linking vitamin D signaling to TLR-mediated antimicrobial responses: TLR-induced expression of another antimicrobial peptide, defensin beta 4, by monocytes requires convergence of both VDR- and IL1β-activation pathways [32].

Together, vitamin-D-mediated induction of antimicrobial peptides (at least partially) explains the success of UV therapy as a way to improve or even cure disease in tuberculosis patients. Nevertheless, additional mechanisms are likely to further complement the antimicrobial effects of 1,25(OH)2D3, as 1,25(OH)2D3 mediates generation of reactive oxygen species in human monocytes and macrophages [33]. Induction of inducible nitric oxide synthase (iNOS) has been proposed as a potential mechanism by which 1,25(OH)2D3 mediates bacterial killing. However, controversial data have been obtained concerning regulation of iNOS expression by 1,25(OH)2D3. In a human macrophage-like cell line, induction of iNOS expression by the hormone was observed, whereas others reported inhibitory actions of 1,25(OH)2D3 on this enzyme [34, 35]. Remarkably, while participating in TLR-induced antimicrobial responses, 1,25(OH)2D3 induces hyporesponsiveness to PAMPS by downregulating the expression of TLR2 and TLR4 on monocytes, probably providing a negative feedback mechanism to prevent excessive TLR activation and to shut down the inflammatory response at a later stage of infection [36].

Vitamin D: modulator of adaptive immune responses

Both in humans and experimental animal models, insufficient levels of vitamin D have been linked to important immune defects in the context of autoimmune disorders. Multiple epidemiological studies show a correlation between areas with low vitamin D supplies (due to insufficient sunlight exposure time or nutritional vitamin D uptake) and incidences of different autoimmune diseases (e.g. type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis). Also in animal models of various autoimmune diseases, vitamin D deficiency has been shown to accelerate disease development (reviewed in [37]).
  • APCs as primary targets for 1,25(OH)2D3

In the light of adaptive immune responses, DCs have been shown to be central targets for VDR agonists [38, 39]. DC differentiation and maturation is potently inhibited by 1,25(OH)2D3, as evidenced by sustained expression of monocytic markers and decreased levels of DC markers, MHC class II, costimulatory molecules (CD40, CD80, CD86), and other maturation-induced surface markers [40, 41, 42, 43]. In addition, 1,25(OH)2D3 dramatically alters DC-derived cytokine and chemokine production: 1,25(OH)2D3-treated DCs express lower levels of IL-12 and IL-23 (known as major cytokines driving Th1- and Th17-differentiation respectively), whereas these cells secrete elevated levels of IL-10 (a cytokine exerting broad spectrum anti-inflammatory activities) and the chemokine macrophage inflammatory protein 3 alfa (MIP3α) [also known as CCL22, a chemokine involved in the recruitment of CCR4-expressing regulatory T cells (Tregs)] [40, 41, 42, 43, 44, 45, 46, 47]. Besides this, 1,25(OH)2D3 treatment of differentiating DCs also disturbs their migratory capacity in response to inflammatory and lymph-node-homing chemokines, although expression of cognate chemokine receptors remained unaffected [42]. A large-scale analysis by our group of the protein profile of DCs using a 2D differential gel-electrophoresis (2D-DIGE) system revealed three protein groups predominantly affected by a VDR agonist, being proteins involved in cytoskeleton structure, protein biosynthesis/proteolysis, and metabolism [48]. Alterations in cytoskeleton proteins may diminish the establishment of or deteriorate existing DC T-cell contacts and decrease secretion of cytokines by T cells.

Besides DCs, the antigen-presenting and T-cell stimulatory capacities of monocytes/macrophages are greatly inhibited by 1,25(OH)2D3, as demonstrated by the inhibitory effects on the surface expression of MHCII and costimulatory molecules, such as CD40, CD80, and CD86 [26, 49]. In addition, 1,25(OH)2D3 inhibits expression of inflammatory mediators in monocytes, including IL-1, IL-6, tumor necrosis factor (TNF)-α, IL-8, and IL-12 [49, 50, 51]. As antigen-presentation and subsequent T-cell activation are the main functions of DCs, 1,25(OH)2D3-mediated DC modulation severely affects T-cell responses. For example, 1,25(OH)2D3-mediated DCs have a reduced capacity to stimulate T-cell proliferation [40, 52]. Moreover, as a result of DC-derived cytokine modulation, 1,25(OH)2D3-conditioned DCs have a lower ability to prime for Th1 and Th17 responses, thereby favoring the emergence of a Th2 phenotype [40, 41, 53]. Importantly, as 1,25(OH)2D3-modulated DCs share many features with tolerogenic DCs (including decreased expression of costimulatory molecules, reduced IL-12, and increased IL-10 production), these cells stimulate the development of Tregs with suppressive capacity. Indeed, different groups have demonstrated the ability of VDR agonists to enhance Treg induction in vitro [44, 54] and in animal models of autoimmune diseases [55, 56, 57]. Importantly, VDR agonists not only give rise to increased numbers of Tregs but also enhance their suppressive capacity [58]. Interestingly, a microarray analysis revealed that induction of DCs with tolerogenic capacities by 1,25(OH)2D3 is not simply caused by its effects on DC differentiation and maturation but rather results from the autonomous regulation of a set of genes unrelated to DC differentiation and maturation [59]. Collectively, these data demonstrate that DCs are key targets for VDR agonists, thereby indirectly inhibiting inflammatory T-cell subsets while favoring the emergence of T cells that resolve inflammation (Fig. 1).
  • Direct actions of 1,25(OH)2D3 on T and B lymphocytes

Besides the profound effects of 1,25(OH)2D3 on T-cell responses via modulation of DC phenotype and function, induction of VDR expression in activated T cells indicates additional direct mechanisms to shape T-cell responses (Fig. 1). In agreement with this, several groups have demonstrated the ability of 1,25(OH)2D3 to directly inhibit antigen- and lectin-stimulated proliferation of human and murine T cells and to alter their cytokine profiles: 1,25(OH)2D3 inhibits production of Th1 cytokines such as IL-2, IFN-γ, and TNF-α and favors the emergence of Th2 cells by upregulating the expression of Th2-specific transcription factors GATA-3 and c-maf and concomitant cytokines, including IL-4 [60, 61, 62, 63]. In addition, production of IL-17, the hallmark cytokine of the newly identified inflammatory Th17 cells, has been shown to be directly suppressed by VDR agonists in T cells [53, 63]. Interestingly, induction of Tregs by VDR agonists does not always require induction of tolerogenic DCs, as a combination of 1,25(OH)2D3 and dexamethasone could give rise to Tregs in vitro in the absence of APCs [64]. These cells produced high levels of IL-10 but no IFN-γ, IL-4, or IL-5 and could potently suppress autoimmune demyelination in vivo in an antigen-specific way. In addition, 1,25(OH)2D3-induced IL-10-producing Tregs have been demonstrated to express high levels of TLR9, and triggering of this receptor abrogates their suppressive capacity, possibly reflecting an integrated mechanism for the temporal shutdown of 1,25(OH)2D3-induced Treg function when infectious agents need to be cleared [65].

Next to T cells, B-cell responses also are controlled by 1,25(OH)2D3. The actions of 1,25(OH)2D3 on B cells were originally believed to result from its ability to modify Th responses. However, more recently, B cells were found to be direct targets for VDR agonists. The 1,25(OH)2D3-mediated effects on B cells include inhibition of proliferation, plasma-cell differentiation, and immunoglobulin secretion, as well as memory B-cell generation and induction of apoptosis [17]. Recently, 1,25(OH)2D3 has been identified as an important regulator of lymphocyte trafficking. DCs of the skin, which can convert locally produced vitamin D3 or 25(OH)D3 into active 1,25(OH)2D3, imprint activated T cells and terminally differentiating B cells with skin-homing properties via 1,25(OH)2D3-mediated induction of the skin-homing receptor CCR10 [18, 66].

Immune consequences of vitamin D insufficiency: clinical implications in chronic kidney disease

Suboptimal levels of 1,25(OH)2D3 are a common finding in chronic kidney disease (CKD) [67, 68]. Therefore most of these patients are at high risk of developing secondary hyperparathyroidism and other complications, including cardiovascular diseases [69]. Importantly, CKD patients not only display impaired levels of 1,25(OH)2D3: also low circulating 25(OH)D3 levels, irrespective of disease progression, are frequently observed in these patients, which further contribute to low 1,25(OH)2D3 levels [70, 71, 72, 73]. Recent studies addressed this issue in pediatric CKD patients and found vitamin D insufficiency and deficiency to be highly prevalent among them [74, 75, 76, 77]. The lack of 25(OH)D3 can rationally be explained in cases of proteinuria, where DBP-bound 25(OH)D3 is lost, but decreased sunlight exposure and malnutrition due to chronic illness, dietary restrictions, and decreased UVB-mediated synthesis of vitamin D3 in the skin of CKD patients compared with individuals with normal kidney function have been proposed to underlie this deficit as well. Replacement therapy with 1,25(OH)2D3 or other VDR agonists in CKD is a commonly used strategy to counteract the detrimental consequences of vitamin D deficiency on mineral and bone health. However, recognition of the widespread nonclassic actions of vitamin D metabolites, together with the increasing amount of epidemiological and experimental data linking inadequate 25(OH)D3 levels to conditions closely reflecting multiple comorbidities of CKD—such as impaired immune function and increased susceptibility to malignancies, cardiovascular disease, and infections—strongly indicate a more extended role for vitamin D metabolites in the pathogenesis and treatment of CKD. Indeed, a number of studies demonstrate that vitamin D deficiency increases the risk for early mortality in hemodialysis patients [78, 79], whereas administration of VDR agonists in these patients has been associated with increased survival, independent of bone- and mineral-related parameters [80, 81, 82]. Despite these data, controversy remains, as a meta-analysis by Palmer et al. did not reveal a clear benefit of vitamin D therapy in CKD patients [83].

Vitamin D insufficiency and CKD-associated immune defects

Considering the importance of the vitamin D endocrine system for normal immune physiology, as highlighted in this review, vitamin D insufficiency or deficiency in CKD patients is likely to contribute to disease-associated immune defects, and therefore, vitamin D therapy might have important implications for immune function in this of group patients (Fig. 2). Remarkably, the two most common causes of death in CKD patients—being, respectively, cardiovascular diseases and infections—have been linked to both impaired vitamin D levels and dysregulated immune responses. CKD is characterized by a state of chronic low-grade inflammation, which translates into an increased risk for cardiovascular disease in end-stage renal disease patients [84]. A wide array of inflammatory biomarkers, including C-reactive protein and IL-6, have been demonstrated to be important predictors of disease outcome. The beneficial effects of active vitamin D on cardiovascular function have been shown to originate from its direct actions on cardiac muscle and the renin-angiotensin-aldosterone system but are also believed to stem in part from its immunomodulatory effects (reviewed in [85]). As inflammation is crucially involved in the processes leading to formation of foam cells and atherosclerotic lesions, the inhibitory effects of 1,25(OH)2D3 on Th1-differentiation, IFN-γ, IL-6, and TNF-α production, together with the stimulatory effects on IL-10 release, are all factors proposed as mechanisms contributing to protective effects of vitamin D on the cardiovascular system. Additionally, the persistent systemic inflammatory response observed in CKD contributes to a further loss of renal function, and vitamin D is believed to play a significant role in this process as well. Vitamin D deficiency was reported to be associated with increased renal inflammation in a variety of renal diseases [86], whereas the anti-inflammatory effects of a 1,25(OH)2D3 analog, paricalcitol, could be demonstrated by inhibition of renal inflammatory infiltration in a mouse model of obstructive nephropathy [87].
Fig. 2

Mechanisms proposed to underlie improved rates of chronic kidney disease (CKD) morbidity and mortality after vitamin D therapy: immune-dependent and -independent mechanisms beyond mineral and bone. Besides direct protective actions on both renal and cardiovascular tissue, the immunomodulatory actions of vitamin D receptor (VDR) agonists are likely to represent an important disease-improving mechanism in CKD patients. Via its anti-inflammatory actions, VDR agonists can reduce the state of chronic inflammation associated with CKD progression, thereby limiting renal infiltration by immune cells and inflammation-related cardiovascular complications, such as atherosclerosis. Moreover, via their potent antimicrobial actions, VDR agonists can improve the ability of CKD patients to combat infectious pathogens, further reducing the high infection rate observed in these individuals

Based on the recent discovery of an essential role of vitamin D in TLR-mediated host defense, it is tempting to speculate on the involvement of this mechanism in the high infection rate observed in CKD patients, with their tendency to display vitamin D deficiency. Vitamin-D-dependent antimicrobial responses might in part explain the survival benefit from increased vitamin D levels seen in hemodialysis patients. Gombart et al. found lower cathelicidin levels in patients who died from infections compared with those who survived, and they observed a modest correlation with circulating levels of 1,25(OH)2D3 but not 25(OH)D3 [88].


Besides its well-established role in the maintenance of mineral homeostasis and bone health, the active vitamin D metabolite, 1,25(OH)2D3, has been identified as a central regulator of normal immune functioning. In addition, the discovery of vitamin-D-activating enzymes expressed in certain immune cells, allowing a local extrarenal activation of vitamin D, has led to the emerging viewpoint of an auto- or paracrine role for vitamin D metabolites in the immune system. This concept is supported by various studies linking vitamin D deficiency or insufficiency to conditions related to dysregulated immune responses, including various autoimmune diseases and infections. Deficient levels of both 1,25(OH)2D3 and 25(OH)D3 are inherent to CKD. Given the immune abnormalities observed in CKD patients, such as systemic low-grade chronic inflammation (contributing to cardiovascular and other complications) and increased susceptibility to infections, modulation of immune responses presumably represents an important mechanism underlying improved disease outcome and mortality rates observed in patients treated with any type of vitamin D metabolite. Moreover, recognition of an auto- and/or paracrine role for vitamin D metabolites in the immune system and other sites in the body emphasizes the need for adequate levels of 25(OH)D3, not only for bone and mineral homeostasis but for global health. In addition, these findings have important implications for the current guidelines concerning vitamin D treatment in CKD patients. Current Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend screening of 25(OH)D3 levels in stage 3–4 CKD patients with elevated PTH concentrations, and similar guidelines exist for stage 2–4 pediatric CKD patients [1, 89]. If serum levels of 25(OH)D3 in these patients drop <30 ng/ml, vitamin D treatment should be initiated, whereas therapy with an active vitamin D sterol (calcitriol, alfacalcidol, paricalcitol, or doxercalciferol) should be preferred at stage 5 disease. However, taking into account the high prevalence of vitamin D insufficiency during all stages of CKD and the growing appreciation of its detrimental consequences on immune and cardiovascular function, the current guidelines should be re-evaluated, considering a careful monitoring of 25(OH)D3 levels during the complete disease course and treatment of vitamin D insufficiency or deficiency from early disease stages on.



This work was supported by grants of the Flemish Research Foundation [Fonds Voor Wetenschappelijk Onderzoek (FWO) Vlaanderen G.0552.06 and G.0649.08, a postdoctoral fellowship for Conny Gysemans and Hannelie Korf and a clinical fellowship for Chantal Mathieu], of the Belgium Program on Interuniversity Poles of Attraction initiated by the Belgian State (IAP P5/17 and P6/40), of the Katholieke Universiteit Leuven (GOA 2004/10 and GOA 2009/10), of the 6th Framework Program of the European Union with acronym SAVEBETA as well as of the 7th Framework Program of the European Union with acronym NAIMIT and of the JDRF Center for Prevention of Beta Cell Therapy in Diabetes [grant number 4-2005-1327].


  1. 1.
    National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–S201Google Scholar
  2. 2.
    Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16:713–716CrossRefPubMedGoogle Scholar
  3. 3.
    Hollis BW (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135:317–322PubMedGoogle Scholar
  4. 4.
    Janssen HC, Samson MM, Verhaar HJ (2002) Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 75:611–615PubMedGoogle Scholar
  5. 5.
    Bouillon R, Bischoff-Ferrari H, Willett W (2008) Vitamin D and health: perspectives from mice and man. J Bone Miner Res 23:974–979CrossRefPubMedGoogle Scholar
  6. 6.
    Holick MF (1997) Photobiology of vitamin D. In: Feldman D, Glorieux FH, Pike J (eds) Vitamin D. Academic Press, San Diego, pp 33–39Google Scholar
  7. 7.
    Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol Renal Physiol 289:F8–F28CrossRefPubMedGoogle Scholar
  8. 8.
    Marcinkowska E (2001) A run for a membrane vitamin D receptor. Biol Signals Recept 10:341–349CrossRefPubMedGoogle Scholar
  9. 9.
    Bikle D (2009) Nonclassic actions of vitamin D. J Clin Endocrinol Metab 94:26–34CrossRefPubMedGoogle Scholar
  10. 10.
    Townsend K, Evans KN, Campbell MJ, Colston KW, Adams JS, Hewison M (2005) Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol 97:103–109CrossRefPubMedGoogle Scholar
  11. 11.
    Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC (1983) 1, 25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221:1181–1183CrossRefPubMedGoogle Scholar
  12. 12.
    Veldman CM, Cantorna MT, DeLuca HF (2000) Expression of 1, 25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 374:334–338CrossRefPubMedGoogle Scholar
  13. 13.
    Takahashi K, Nakayama Y, Horiuchi H, Ohta T, Komoriya K, Ohmori H, Kamimura T (2002) Human neutrophils express messenger RNA of vitamin D receptor and respond to 1alpha, 25-dihydroxyvitamin D3. Immunopharmacol Immunotoxicol 24:335–347CrossRefPubMedGoogle Scholar
  14. 14.
    Monkawa T, Yoshida T, Hayashi M, Saruta T (2000) Identification of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression in macrophages. Kidney Int 58:559–568CrossRefPubMedGoogle Scholar
  15. 15.
    Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, Rutgeerts O, Saint-Arnaud R, Bouillon R, Mathieu C (2000) Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 120:139–146CrossRefPubMedGoogle Scholar
  16. 16.
    Hewison M, Freeman L, Hughes SV, Evans KN, Bland R, Eliopoulos AG, Kilby MD, Moss PA, Chakraverty R (2003) Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol 170:5382–5390PubMedGoogle Scholar
  17. 17.
    Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE (2007) Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:1634–1647PubMedGoogle Scholar
  18. 18.
    Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, Butcher EC (2007) DCs metabolize sunlight-induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat Immunol 8:285–293CrossRefPubMedGoogle Scholar
  19. 19.
    van Etten E, Stoffels K, Gysemans C, Mathieu C, Overbergh L (2008) Regulation of vitamin D homeostasis: implications for the immune system. Nutr Rev 66:S125–S134CrossRefPubMedGoogle Scholar
  20. 20.
    Kreutz M, Andreesen R, Krause SW, Szabo A, Ritz E, Reichel H (1993) 1, 25-dihydroxyvitamin D3 production and vitamin D3 receptor expression are developmentally regulated during differentiation of human monocytes into macrophages. Blood 82:1300–1307PubMedGoogle Scholar
  21. 21.
    Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770–1773CrossRefPubMedGoogle Scholar
  22. 22.
    Chan TY (2000) Vitamin D deficiency and susceptibility to tuberculosis. Calcif Tissue Int 66:476–478CrossRefPubMedGoogle Scholar
  23. 23.
    Kankova M, Luini W, Pedrazzoni M, Riganti F, Sironi M, Bottazzi B, Mantovani A, Vecchi A (1991) Impairment of cytokine production in mice fed a vitamin D3-deficient diet. Immunology 73:466–471PubMedGoogle Scholar
  24. 24.
    Giulietti A, Gysemans C, Stoffels K, van Etten E, Decallonne B, Overbergh L, Bouillon R, Mathieu C (2004) Vitamin D deficiency in early life accelerates Type 1 diabetes in non-obese diabetic mice. Diabetologia 47:451–462CrossRefPubMedGoogle Scholar
  25. 25.
    Griffin MD, Xing N, Kumar R (2003) Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 23:117–145CrossRefPubMedGoogle Scholar
  26. 26.
    Xu H, Soruri A, Gieseler RK, Peters JH (1993) 1, 25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand J Immunol 38:535–540CrossRefPubMedGoogle Scholar
  27. 27.
    Rook GA, Steele J, Fraher L, Barker S, Karmali R, O’Riordan J, Stanford J (1986) Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57:159–163PubMedGoogle Scholar
  28. 28.
    Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, Tavera-Mendoza L, Lin R, Hanrahan JW, Mader S, White JH (2004) Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 173:2909–2912PubMedGoogle Scholar
  29. 29.
    Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G (2007) Induction of cathelicidin in normal and CF bronchial epithelial cells by 1, 25-dihydroxyvitamin D(3). J Cyst Fibros 6:403–410CrossRefPubMedGoogle Scholar
  30. 30.
    Gombart AF, O’Kelly J, Saito T, Koeffler HP (2007) Regulation of the CAMP gene by 1, 25(OH)2D3 in various tissues. J Steroid Biochem Mol Biol 103:552–557CrossRefPubMedGoogle Scholar
  31. 31.
    Krutzik SR, Hewison M, Liu PT, Robles JA, Stenger S, Adams JS, Modlin RL (2008) IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol 181:7115–7120PubMedGoogle Scholar
  32. 32.
    Liu PT, Schenk M, Walker VP, Dempsey PW, Kanchanapoomi M, Wheelwright M, Vazirnia A, Zhang X, Steinmeyer A, Zugel U, Hollis BW, Cheng G, Modlin RL (2009) Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One 4:e5810CrossRefPubMedGoogle Scholar
  33. 33.
    Sly LM, Lopez M, Nauseef WM, Reiner NE (2001) 1alpha, 25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. J Biol Chem 276:35482–35493CrossRefPubMedGoogle Scholar
  34. 34.
    Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, Kwiatkowski D (1998) 1, 25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun 66:5314–5321PubMedGoogle Scholar
  35. 35.
    Chang JM, Kuo MC, Kuo HT, Hwang SJ, Tsai JC, Chen HC, Lai YH (2004) 1-alpha, 25-Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells. J Lab Clin Med 143:14–22CrossRefPubMedGoogle Scholar
  36. 36.
    Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J, Zugel U, Steinmeyer A, Pollak A, Roth E, Boltz-Nitulescu G, Spittler A (2006) Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 36:361–370CrossRefPubMedGoogle Scholar
  37. 37.
    Cantorna MT, Mahon BD (2004) Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 229:1136–1142Google Scholar
  38. 38.
    van Etten E, Mathieu C (2005) Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97:93–101CrossRefPubMedGoogle Scholar
  39. 39.
    Baeke F, van Etten E, Overbergh L, Mathieu C (2007) Vitamin D3 and the immune system: maintaining the balance in health and disease. Nutr Res Rev 20:106–118CrossRefPubMedGoogle Scholar
  40. 40.
    Penna G, Adorini L (2000) 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164:2405–2411PubMedGoogle Scholar
  41. 41.
    van Halteren AG, van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C (2002) Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1, 25 dihydroxyvitamin D(3). Diabetes 51:2119–2125CrossRefPubMedGoogle Scholar
  42. 42.
    Gauzzi MC, Purificato C, Donato K, Jin Y, Wang L, Daniel KC, Maghazachi AA, Belardelli F, Adorini L, Gessani S (2005) Suppressive effect of 1alpha, 25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol 174:270–276PubMedGoogle Scholar
  43. 43.
    Pedersen AW, Holmstrom K, Jensen SS, Fuchs D, Rasmussen S, Kvistborg P, Claesson MH, Zocca MB (2009) Phenotypic and functional markers for 1alpha, 25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin Exp Immunol 157:48–59CrossRefPubMedGoogle Scholar
  44. 44.
    Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, Adorini L (2007) 1, 25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 178:145–153PubMedGoogle Scholar
  45. 45.
    Zhu J, Paul WE (2008) CD4 T cells: fates, functions, and faults. Blood 112:1557–1569CrossRefPubMedGoogle Scholar
  46. 46.
    Mosser DM, Zhang X (2008) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226:205–218CrossRefPubMedGoogle Scholar
  47. 47.
    D’Ambrosio D (2006) Regulatory T cells: how do they find their space in the immunological arena? Semin Cancer Biol 16:91–97CrossRefPubMedGoogle Scholar
  48. 48.
    Ferreira GB, van Etten E, Lage K, Hansen DA, Moreau Y, Workman CT, Waer M, Verstuyf A, Waelkens E, Overbergh L, Mathieu C (2009) Proteome analysis demonstrates profound alterations in human dendritic cell nature by TX527, an analogue of vitamin D. Proteomics 9:3752–3764CrossRefPubMedGoogle Scholar
  49. 49.
    Almerighi C, Sinistro A, Cavazza A, Ciaprini C, Rocchi G, Bergamini A (2009) 1Alpha, 25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine 45:190–197CrossRefPubMedGoogle Scholar
  50. 50.
    D’Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F, Panina-Bordignon P (1998) Inhibition of IL-12 production by 1, 25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 101:252–262CrossRefPubMedGoogle Scholar
  51. 51.
    Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C (2007) Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1, 25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 77:47–57CrossRefPubMedGoogle Scholar
  52. 52.
    van Halteren AG, Tysma OM, van Etten E, Mathieu C, Roep BO (2004) 1alpha, 25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 23:233–239CrossRefPubMedGoogle Scholar
  53. 53.
    Tang J, Zhou R, Luger D, Zhu W, Silver PB, Grajewski RS, Su SB, Chan CC, Adorini L, Caspi RR (2009) Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol 182:4624–4632CrossRefPubMedGoogle Scholar
  54. 54.
    Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E, Colonna M, Adorini L (2005) Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1, 25-dihydroxyvitamin D3. Blood 106:3490–3497CrossRefPubMedGoogle Scholar
  55. 55.
    Ghoreishi M, Bach P, Obst J, Komba M, Fleet JC, Dutz JP (2009) Expansion of antigen-specific regulatory T cells with the topical vitamin d analog calcipotriol. J Immunol 182:6071–6078CrossRefPubMedGoogle Scholar
  56. 56.
    Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L (2002) A 1alpha, 25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 51:1367–1374CrossRefPubMedGoogle Scholar
  57. 57.
    Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM (2008) Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 324:23–33CrossRefPubMedGoogle Scholar
  58. 58.
    Gorman S, Kuritzky LA, Judge MA, Dixon KM, McGlade JP, Mason RS, Finlay-Jones JJ, Hart PH (2007) Topically applied 1, 25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol 179:6273–6283PubMedGoogle Scholar
  59. 59.
    Szeles L, Keresztes G, Torocsik D, Balajthy Z, Krenacs L, Poliska S, Steinmeyer A, Zuegel U, Pruenster M, Rot A, Nagy L (2009) 1, 25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J Immunol 182:2074–2083CrossRefPubMedGoogle Scholar
  60. 60.
    Bhalla AK, Amento EP, Serog B, Glimcher LH (1984) 1, 25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 133:1748–1754PubMedGoogle Scholar
  61. 61.
    Rigby WF, Stacy T, Fanger MW (1984) Inhibition of T lymphocyte mitogenesis by 1, 25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 74:1451–1455CrossRefPubMedGoogle Scholar
  62. 62.
    Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A (2001) 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167:4974–4980PubMedGoogle Scholar
  63. 63.
    Borgogni E, Sarchielli E, Sottili M, Santarlasci V, Cosmi L, Gelmini S, Lombardi A, Cantini G, Perigli G, Luconi M, Vannelli GB, Annunziato F, Adorini L, Serio M, Crescioli C (2008) Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. Endocrinology 149:3626–3634CrossRefPubMedGoogle Scholar
  64. 64.
    Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O’Garra A (2002) In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195:603–616CrossRefPubMedGoogle Scholar
  65. 65.
    Urry Z, Xystrakis E, Richards DF, McDonald J, Sattar Z, Cousins DJ, Corrigan CJ, Hickman E, Brown Z, Hawrylowicz CM (2009) Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha, 25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest 119:387–398PubMedGoogle Scholar
  66. 66.
    Shirakawa AK, Nagakubo D, Hieshima K, Nakayama T, Jin Z, Yoshie O (2008) 1, 25-dihydroxyvitamin D3 induces CCR10 expression in terminally differentiating human B cells. J Immunol 180:2786–2795PubMedGoogle Scholar
  67. 67.
    Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38CrossRefPubMedGoogle Scholar
  68. 68.
    Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H (1999) Serum levels of 1, 25-dihydroxyvitamin D, 24, 25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 55:1019–1027CrossRefPubMedGoogle Scholar
  69. 69.
    Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G (2006) Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. J Nephrol 19:566–577PubMedGoogle Scholar
  70. 70.
    LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45:1026–1033CrossRefPubMedGoogle Scholar
  71. 71.
    Shah N, Bernardini J, Piraino B (2005) Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 25:362–366PubMedGoogle Scholar
  72. 72.
    Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ (2004) Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24:503–510CrossRefPubMedGoogle Scholar
  73. 73.
    Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR (2007) Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 11:315–321CrossRefPubMedGoogle Scholar
  74. 74.
    Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK (2008) Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 23:1831–1836CrossRefPubMedGoogle Scholar
  75. 75.
    Belostotsky V, Mughal MZ, Berry JL, Webb NJ (2008) Vitamin D deficiency in children with renal disease. Arch Dis Child 93:959–962CrossRefPubMedGoogle Scholar
  76. 76.
    Seeherunvong W, Abitbol CL, Chandar J, Zilleruelo G, Freundlich M (2009) Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr 154:906–911CrossRefPubMedGoogle Scholar
  77. 77.
    Ali FN, Arguelles LM, Langman CB, Price HE (2009) Vitamin D deficiency in children with chronic kidney disease: uncovering an epidemic. Pediatrics 123:791–796CrossRefPubMedGoogle Scholar
  78. 78.
    Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004–1013CrossRefPubMedGoogle Scholar
  79. 79.
    Inaguma D, Nagaya H, Hara K, Tatematsu M, Shinjo H, Suzuki S, Mishima T, Kurata K (2008) Relationship between serum 1, 25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin Exp Nephrol 12:126–131CrossRefPubMedGoogle Scholar
  80. 80.
    Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115–1125CrossRefPubMedGoogle Scholar
  81. 81.
    Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG (2006) Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70:1858–1865CrossRefPubMedGoogle Scholar
  82. 82.
    Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, Gutierrez O, Camargo CA Jr, Melamed M, Norris K, Stampfer MJ, Powe NR, Thadhani R (2008) Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 19:1379–1388CrossRefPubMedGoogle Scholar
  83. 83.
    Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147:840–853PubMedGoogle Scholar
  84. 84.
    Stenvinkel P (2006) Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 11:36–41CrossRefGoogle Scholar
  85. 85.
    Levin A, Li YC (2005) Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 68:1973–1981CrossRefPubMedGoogle Scholar
  86. 86.
    Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV, Raymond NT, Howie AJ, Cockwell P, Stewart PM, Hewison M (2008) Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 74:1343–1353CrossRefPubMedGoogle Scholar
  87. 87.
    Tan X, Wen X, Liu Y (2008) Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 19:1741–1752CrossRefPubMedGoogle Scholar
  88. 88.
    Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo CA Jr, Koeffler HP, Thadhani R (2009) Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis 48:418–424CrossRefPubMedGoogle Scholar
  89. 89.
    National Kidney Foundation (2005) K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S1–S121Google Scholar

Copyright information

© IPNA 2010

Authors and Affiliations

  • Femke Baeke
    • 1
  • Conny Gysemans
    • 1
  • Hannelie Korf
    • 1
  • Chantal Mathieu
    • 1
  1. 1.Laboratory of Experimental Medicine and Endocrinology (LEGENDO)Katholieke Universiteit Leuven (KUL)LeuvenBelgium

Personalised recommendations